MSB 2.22% $1.10 mesoblast limited

Ann: Half Year Report and Accounts (including Appendix 4D), page-16

  1. 15,490 Posts.
    lightbulb Created with Sketch. 5577
    BMT-CTN is paying for 80% of the aGVHD trial


    @Fastback6666 I'm not sure that is the case .... well it is not what it says in the original GVHD trial notification and / or today's HY Report (see below extract) ?


    It is my understanding that the costs will be shared by BMT CTN and Mesoblast, but I don't recall seeing confirmation that BMT CTN are contributing 80% of the total costs ? If the 80% figure you are quoting is from the ASX announcements below, then I am not sure you are reading it right because that isn't what it says ? It says BMT CTN centers are responsible for approximately 80% of all US allogeneic bone marrow transplants (BMTs) not 80% of the upcoming Mesoblast sr-GVHD trial costs ?


    " Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a body including centers responsible for approximately 80% of all US allogeneic BMTs, "


    Happy for you to show me where you got this 80% figure from if it is from somewhere else and it is the case that BMT CTN are paying this large percentage of costs ?


    upload_2024-2-29_15-23-8.png


    From today's HY Report:

    upload_2024-2-29_15-24-2.png
    Last edited by col69: 29/02/24
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.10
Change
-0.025(2.22%)
Mkt cap ! $1.261B
Open High Low Value Volume
$1.14 $1.16 $1.09 $4.781M 4.305M

Buyers (Bids)

No. Vol. Price($)
28 356702 $1.10
 

Sellers (Offers)

Price($) Vol. No.
$1.10 3365 3
View Market Depth
Last trade - 13.40pm 29/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.